Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 28 of the 29 references it cites were found in a registry or an index.

Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial

Open access
Mateos, María-Victoria, Oriol, Albert, Martínez-López, Joaquín, Gutiérrez, Norma, Teruel, Ana-Isabel, de Paz, Raquel, García-Laraña, José, Bengoechea, Enrique, Martín, Alejandro, Mediavilla, Joaquín Díaz, Palomera, Luis, de Arriba, Felipe, González, Yolanda, Hernández, Jose-Mariano, Sureda, Ana, Bello, José-Luis, Bargay, Joan, Peñalver, Francisco-Javier, Ribera, José-María, Martín-Mateos, María-Luisa, García-Sanz, Ramón, Cibeira, María-Teresa, Ramos, María-Luisa Martín, Vidriales, María-Belén, Paiva, Bruno, Montalbán, María-Angeles, Lahuerta, Juan-José, Bladé, Joan, Miguel, Jesús-Fernando San · 2010 · The Lancet Oncology

Abstract

Background Bortezomib plus melphalan and prednisone (VMP) is significantly better than melphalan plus prednisone alone for elderly patients with untreated multiple myeloma; however, toxic effects are high. We investigated a novel and less intensive bortezomib-based regimen to maintain efficacy and to reduce toxic effects.Methods Between March, 2006, and October, 2008, 260 patients with untreated multiple myeloma, 65 years and older, from 63 Spanish centres, were randomly assigned to receive six cycles of VMP (n=130) or bortezomib plus thalidomide and prednisone (VTP; n=130) as induction therapy, consisting of one cycle of bortezomib twice per week for 6 weeks (1·3 mg/m² on days 1, 4, 8, 11, 22, 25, 29, and 32), plus either melphalan (9 mg/m² on days 1-4) or daily thalidomide (100 mg), and prednisone (60 mg/m² on days 1-4). The first cycle was followed by five cycles of bortezomib once per week for 5 weeks (1·3 mg/m² on days 1, 8, 15, and 22) plus the same doses of melphalan plus prednisone and thalidomide plus prednisone. 178 patients completed the six induction cycles and were randomly assigned to maintenance therapy with bortezomib plus prednisone (n=87) or bortezomib plus thalidomide (n=91), consisting of one conventional cycle of bortezomib for 3 weeks (1·3 mg/m² on days 1, 4, 8, and 11) every 3 months, plus either prednisone (50 mg every other day) or thalidomide (50 mg per day), for up to 3 years. Treatment codes were generated with a computerised random number generator, and neither participants nor study personnel were masked to treatment. The primary endpoint was response rate in induction and maintenance phases. Analysis was by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT00443235.Findings In the induction phase, 105 (81%) patients in the VTP group and 104 (80%) in the VMP group achieved partial responses or better (p=0·9), including 36 (28%) and 26 (20%) complete remissions, respectively (p=0·2). Treatment with VTP resulted in more serious adverse events (40 [31%] vs 20 [15%], p=0·01) and discontinuations (22 [17%] vs 15 [12%], p=0·03) than did treatment with VMP. The most common toxicities (grade 3 or worse) were infections (one [1%] in the VTP group vs nine [7%] in the VMP group), cardiac events (11 [8%] vs 0), and peripheral neuropathy (nine [7%] vs 12 [9%]). After maintenance therapy, the complete remission rate was 42% (40 [44%] patients in complete remission in the bortezomib plus thalidomide group, 34 [39%] in the bortezomib plus prednisone group). No grade 3 or worse haematological toxicities were recorded during maintenance therapy; two (2%) patients in the bortezomib plus prednisone group and six (7%) in the bortezomib plus thalidomide group developed peripheral neuropathy.Interpretation Reduced-intensity induction with a bortezomib-based regimen, followed by maintenance, is a safe and effective treatment for elderly patients with multiple myeloma.Funding Pethema (Spanish Program for the Treatment of Hematologic Diseases).

Overview

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(10)70187-x

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 29 references

Cited by

See all 460

Metadata

Authors
Mateos, M.-V., Oriol, A., Martínez-López, J., Gutiérrez, N., Teruel, A.-I., de Paz, R., García-Laraña, J., Bengoechea, E., Martín, A., Mediavilla, J. D., Palomera, L., de Arriba, F., González, Y., Hernández, J.-M., Sureda, A., Bello, J.-L., Bargay, J., Peñalver, F.-J., Ribera, J.-M., Martín-Mateos, M.-L., García-Sanz, R., Cibeira, M.-T., Ramos, M.-L. M., Vidriales, M.-B., Paiva, B., Montalbán, M.-A., Lahuerta, J.-J., Bladé, J., & Miguel, J.-F. S.
Affiliations
  • Complejo Hospitalario de Salamanca (ES)
  • Hospital Clínico Universitario de Valencia (ES)
  • Donostiako Unibertsitate Ospitalea (ES)
  • Hospital Clínico San Carlos (ES)
  • Hospital Clínico Universitario Lozano Blesa (ES)
  • Hospital Universitari de Girona Doctor Josep Trueta (ES)
  • Universidade de Santiago de Compostela (ES)
  • Hospital Son Llatzer (ES)
  • Hospital Universitario Fundación Alcorcón (ES)
  • Hospital San Pedro de Alcántara (ES)
  • Hospital Clínic de Barcelona (ES)
  • Hospital Universitario 12 De Octubre (ES)
Venue
The Lancet Oncology
Publisher
Elsevier BV
Published
2010-10
Volume
11
Issue
10
Pages
934-941
ISSN
1470-2045 (ISSN-L)
OpenAlex
W2134902298
Cited by
458
References
29
Citations by year
2026: 5 · 2025: 7 · 2024: 6 · 2023: 12 · 2022: 9 · 2021: 16 · 2020: 24 · 2019: 24 · 2018: 30 · 2017: 28 · 2016: 43 · 2015: 46 · 2014: 41 · 2013: 59 · 2012: 52
FWCI
32.83
Type
journal article
Language
en
Open access
Licence
  • cc-by-nc-nd
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Locations
  • The Lancet Oncology (publishedVersion)
  • PubMed (publishedVersion)
  • Hispana (publishedVersion, cc-by-nc-nd)
  • Gredos (University of Salamanca) (submittedVersion, cc-by-nc-nd)
Funders
Johnson and Johnson
Topics
  • Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
  • Health Sciences › Medicine › Oncology › Bone health and treatments
  • Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
Keywords
multiple myeloma, elderly patients, bortezomib, thalidomide, melphalan, prednisone, induction therapy, maintenance therapy, VMP regimen, treatment toxicity, progression-free survival, overall survival, treatment intensity reduction, proteasome inhibitor combination therapy, neuropathy, neutropenia
MeSH terms
Bortezomib, Age Factors, Aged, Antineoplastic Combined Chemotherapy Protocols, Boronic Acids, Drug Administration Schedule, Female, Humans, Male, Melphalan, Multiple Myeloma, Prednisone, Protease Inhibitors, Pyrazines, Risk Factors, Spain, Thalidomide, Time Factors, Proportional Hazards Models, Treatment Outcome, Risk Assessment, Antineoplastic Agents, Alkylating, Angiogenesis Inhibitors, Kaplan-Meier Estimate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. https://app.cochat.ai/papers/10.1016/s1470-2045(10)70187-x
The paper
Mateos, M.-V., Oriol, A., Martínez-López, J., Gutiérrez, N., Teruel, A.-I., de Paz, R., García-Laraña, J., Bengoechea, E., Martín, A., Mediavilla, J. D., Palomera, L., de Arriba, F., González, Y., Hernández, J.-M., Sureda, A., Bello, J.-L., Bargay, J., Peñalver, F.-J., Ribera, J.-M., . . . Miguel, J.-F. S. (2010). Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(10)70187-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.